Regulatory Flexibility For Rare Diseases: How Do You Routinize Elasticity?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tries to MaPP out how and when reviewers can be flexible, moving from 'one-off' to 'boutique' evaluation.